Gilead Adefovir Hep B Resistance Potential Shows Need For Combo Trials
Executive Summary
Gilead adefovir combination studies could address concerns about the potential for developing viral resistance with single-agent use of the drug for chronic hepatitis B, Gilead VP-Clinical Research Carol Brosgart, MD, told an FDA advisory committee Aug. 6
You may also be interested in...
Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005
Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals
Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005
Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals
Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.
Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting